Aytu BioScience Inc. (AYTU)’s Financial Results Comparing With Allogene Therapeutics Inc. (NASDAQ:ALLO)

As Biotechnology companies, Aytu BioScience Inc. (NASDAQ:AYTU) and Allogene Therapeutics Inc. (NASDAQ:ALLO) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aytu BioScience Inc. 4.76M 3.95 10.37M -7.14 0.00
Allogene Therapeutics Inc. N/A 0.00 211.50M 0.00 0.00

Table 1 highlights Aytu BioScience Inc. and Allogene Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Aytu BioScience Inc. -217.86% -73.8% -39.6%
Allogene Therapeutics Inc. 0.00% 0% 0%

Liquidity

The Current Ratio and a Quick Ratio of Aytu BioScience Inc. are 4.7 and 4.4. Competitively, Allogene Therapeutics Inc. has 1.6 and 1.6 for Current and Quick Ratio. Aytu BioScience Inc.’s better ability to pay short and long-term obligations than Allogene Therapeutics Inc.

Analyst Ratings

The Recommendations and Ratings for Aytu BioScience Inc. and Allogene Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aytu BioScience Inc. 0 0 0 0.00
Allogene Therapeutics Inc. 0 0 1 3.00

Competitively the consensus price target of Allogene Therapeutics Inc. is $40, which is potential 49.59% upside.

Institutional and Insider Ownership

Institutional investors held 10.4% of Aytu BioScience Inc. shares and 52.3% of Allogene Therapeutics Inc. shares. Insiders held roughly 13.4% of Aytu BioScience Inc.’s shares. On the other hand, insiders held about 21.2% of Allogene Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aytu BioScience Inc. -13.82% -10.17% 20.45% -76.07% -90.47% 33.77%
Allogene Therapeutics Inc. 0.66% 5.31% 4.72% 0% 0% 18.6%

For the past year Aytu BioScience Inc. was more bullish than Allogene Therapeutics Inc.

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.